Summary of Key 340B Omnibus Guidance Proposals

Polsinelli
Contact

As noted in our previous client alert, the Health Resources and Services Administration (“HRSA”) released its highly anticipated proposed 340B Drug Pricing Program Omnibus Guidance (“Guidance”). The Guidance offers updated HRSA policies and interpretations that apply to 340B stakeholders, including significant changes to the patient definition. The Guidance can be found here. Polsinelli has completed its initial assessment of the Guidance and developed a comprehensive summary of key proposals put forth by HRSA. Our assessment includes:

- A section-by-section review of key changes to existing HRSA guidance;

- Identification of potential implications of the Guidance on Covered Entities;

- Recommended next steps, where applicable.

Please see full publication below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Attorney Advertising.

© Polsinelli

Written by:

Polsinelli
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Polsinelli on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide